Resultado da Busca
25 de mai. de 2024 · Background: Early-onset colorectal cancer (EO-CRC) is defined as colorectal cancer diagnosed before the age of 50 years, and its incidence has been increasing over the last decade, now accounting for 10% of all new CRC diagnoses. Average-onset colorectal cancer (AO-CRC) has shown a steady decline in its incidence and related mortality over the past 20 years. The disparities in outcomes and ...
13 de mai. de 2024 · Yoon J, Koo K-H, Choi K-Y: MEK1/2 inhibitors AS703026 and AZD6244 may Be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res 71:445-453, 2011
15 de mai. de 2024 · In the case of some common cancers, such as colorectal cancer (CRC), existing research is often restricted to limited populations (e.g., the elderly, or individuals with schizophrenia only) and rarely addresses care after diagnosis (Protani et al., Reference Protani, Alotiby, Seth, Lawrence, Jordan, Logan, Kendall, Siskind, Sara and Kisely 2022 ...
27 de mai. de 2024 · Insights on the "Drugs For Metastatic Pancreatic Cancer Market" contribution of various segments including Country and Region wise Historic data (2018 to 2023), and Forecast Market Size (2024 to ...
24 de mai. de 2024 · Bevacizumab and anti-epidermal growth factor receptor-blocking (anti-EGFR) agents plus chemotherapy are first-line therapies for metastatic colorectal cancer (mCRC). Conversion surgery may improve outcomes; however, the extent to which it explains the difference in mortality rates among treatments is unclear. Herein, we aimed to assess the effects of conversion surgery on survival outcomes of ...
23 de mai. de 2024 · U.S & Europe Colorectal Cancer Diagnosis and Therapeutics Market 2024 |Share, Regional Outlook, Competitive Strategies & Forecast up to 2032 Report this article Consumer Trends Chronicle 24
13 de mai. de 2024 · Pembrolizumab, a monoclonal antibody against PD-1, has shown limited efficacy in patients with microsatellite stable or mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (CRC). We evaluated vicriviroc (small-molecule C-C motif chemokine ligand 5 antagonist) plus pembrolizumab in patients with advanced or metastatic MSS/pMMR CRC
